Assessment of the efficacy of rehabilitation treatment with botulinum toxin in patients with cerebral palsy by means of objective gait analysis for patient qualification;Ocena skutecznoéci leczenia rehabilitacyjnego toksyna̧ botulinowa̧ pacjentów z mózgowym porazeniem dzieciȩcym przy zastosowanu obiektywnej analizy chodu do kwalifikacji pacjentów

Rehabilitacja Medyczna

Volumn 11, Issue 1, 2007, Pages 9-16

  Śwlȩcicka, Anna ^a   Syczewska, Małgorzata ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Botulinum toxin; Cerebral palsy; Gait analysis; Rehabilitation; Treatment

Indexed keywords

EID: 34547339653     PISSN: 14279622     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pidcock F.S.: The emerging role of therapeutic botulinum toxine in treatment of cerebral palcy. J. Pediatr., 2004; 145: S33-S35
2. Sheean G.L.: Botulinum treatment of spasticity: why it is so difficult to show a functional benefit? Curr. Opin. Neural., 2001; 14: 771-776
3. Bache C.E., Selber P., Graham H.K.: The management of spastic diplegia. Curr. Orthopaed, 2003; 17: 88-104
4. Graham H.K., Aoki K.R., Autti-Rämö, Boyd R.N., Delgado, M.R., Gaebler-Spira D.J., Gormley M.E., Guyer B.M., Heinen F., Holton A.F., Matthews D., Molenaers G., Motta F., Ruiz P.J.G., Wissel J.: Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait & Posture, 2000; 11:67-79
5. Becher J.: The use of gait analysis for a treatment plan to improve gait. Konferencja PTR Konstancin, maj 2004
6. Berweck S., Keinen F.: Treatment of cerebral palsy with botulinum toxin principles. Clinical practice atlas. Child & Brain, Bonn, Berlin 2003
7. Morris S.: Skale Ashworth'a i Tardieu - znaczenie kliniczne w ocenie spastyczności wśród dorostych i pediatrycznych pacjentów neurologicznych. Rehabilitacja Medyczna, 2002; 6: 9-16
8. Pandyan A.D., Price C.I.M., Rodgers H., Barnes M.P., Johnson G.R.: Biomechanical examination of a commonly used measure of spasticity. Clin. Biomech., 2001; 16: 859-865
9. Tuzson A.E., Granata K.P., Abel M.F.: - Spastic velocity threshold constraints functional performance in cerebral palsy - Arch. Phys. Med. Rehabil., 2003; 84: 1363-1368
10. Pierce P., Orendurff M., Sienko Thomas S.: Gait parameters norms for children ages 6-14. Gait & Posture, 2002; 16 (1): S53-S54
11. Hof A.: Normalised Temporal-Spatial parameters. CGA Normative Gait Database, http://guardian.curtin.edu.au:16080/cga/
12. Öberg T., Karsznia A., Öberg K.: Basic gait parameters: Reference data for normal subjects, 10-79 years of age. J. Rehabil. Res & Develp., 1993; 30: 210-223
13. Roussounis H.S., Bhakta B.B., Ubhi T., Ives H.: Evaluation of botulinum toxin type A treatment in lower limb spasticity in childhood cerebral palsy. A randomized double-blind placebo-controlled trial. Eur. J. Paediatr. Neurol., 1999; 3: A149-A150
14. Crouchman M.: Principles of management of cerebral palsy - Current Paediatrics, 2000; 10: 167-171
15. Sarioglu B., Serdaloglu G., Tutuncuoglu S., Ozer E.A.: The use of botulinum toxin type A treatemnt in children with spasticity. Pediatr. Neurol., 2003; 29: 299-301
16. Gage J.: The clinical use of kinetics for evaluation of pathological gait in CP. J. Bone Jt. Surg., 1994; 76-A: 622-631
17. Bache C.E., Selber P., Graham H.K.: The management of spastic diplegia. Current Orthopaed., 2003; 17: 88-104
18. Sutherland D.H., Kaufman K.R, Wyatt M.P., Chambers H.G., Mubarak S.J.: Double-blind study of botulinum toxin Ainjections into the gastrocnemius muscle in patients with cerebral palsy. Gait & Posture, 1999; 10:1-10
19. Morton R.E., Murray-Leslie C.: The role of botulinum toxin in the management of cerebral palsy. Current Paediatrics, 2001; 11: 235-239
20. Pidcock F. The emerging role of therapeutic botulinum toxin in the treatment of cerebral palsy. J. Pediatr., 2004; 145: S33-S35